



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/740,256	12/18/2003	James E. Dahlberg	FORS-08497	1902
72960 7590 12/30/2009				
Casimir Jones, S.C. 2275 DEMING WAY, SUITE 310 MIDDLETON, WI 53562				
EXAMINER				
SCHULTZ, JAMES				
ART UNIT		PAPER NUMBER		
1633				
MAIL DATE		DELIVERY MODE		
12/30/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/740,256

Applicant(s)

DAHLBERG ET AL.

Examiner

JD SCHULTZ

Art Unit

1633

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 32-71 and 73-80 is/are pending in the application.
- 4a) Of the above claim(s) 35, 37 and 38 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 32-34, 36, 39-71 and 73-80 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB-06)
Paper No(s)/Mail Date ____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(c), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(c) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 25, 2009 has been entered.

Status of Application/Amendment/Claims

Claims 32-71, and 73-80, filed November 25, 2009, are pending. Claims 35, 37, and 38 are withdrawn pursuant to the restriction requirement mailed 5/12/2005. Claims 32-34, 36, 39-71, and 73-80 are the subject of the present Official action.

Claim Rejections - 35 USC § 103

The following rejection(s) are made in view of applicant's amendment. Applicants arguments are rendered moot based upon this new grounds of rejection.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim(s) 32, 34, 35, 37-41, 48-54, 57, 60, 61, 63-65, 73-75, 76- and 78, are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. J Mol Diagn. 2000 May;2(2):97-104) in view of Dattagupta et al. (U. S. Patent Number 5,215,899), Lane et al. (U.S. 5,770,365), Prudent et al. (U.S. 5,985,557), Rather (U.S. 5,858,367), (U.S. 5,593,835), and Lau et al. Science. 26 October 2001. Vol. 294: Pages 858-862).

With regard to claim(s) 32 and 34, steps a-d of the claimed invention generally encompass an assay, which was known at the time of invention as an Invader Assay (see also Prudent, U.S. 5,985,557), further comprising the use of a probe that when hybridized to the target nucleic acid forms a duplex secondary structure.

Ledford teaches a homogeneous Invader microtitre plate FRET assay (abstract; fig. 1; pg. 100, Invader Assay, for example). Specifically, Ledford teaches a method comprising: a) contacting a target nucleic acids with unlabeled probes forming a detection structure (fig. 1, Invader Oligonucleotide, WT Probe, invasive cleavage structure, for example); b) reacting the detection structure with nuclease that cleaves the detection structure (fig. 1, released flap; pg. 98-

99, col. 1, Cleavase, for example); c) dissociating the target nucleic acid from the unlabeled probes (pg. 99, col. 1, probe turnover, for example); and d) detecting modified detection structure (fig.1, FRET detection of released flap; pg. 98-99, col. 1, FRET, for example).

With regard to claim(s) 39-41, Ledford teaches FRET detection (fig.1, FRET detection of released flap; pg. 98-99, col. 1, FRET, for example).

With regard to claim(s) 48 and 49, Ledford teaches detection of a mutation, i.e. specific type of nucleic acid (abstract; fig. 2, Leiden mutation, for example).

With regard to claim(s) 50, Ledford teaches a cell lysate (pg. 99, col. 2, sample prep., for example).

With regard to claim(s) 52 and 53, Ledford teaches detection of a mutation, i.e. specific type of nucleic acid within a plurality of different nucleic acids (abstract; fig. 2, Leiden mutation, for example).

With regard to claim(s) 32, 60, and 61, refer to the rejection of claim(s) 1 above.

With regard to claim(s) 63-65, refer to the rejection of claim(s) 39-41 above.

With regard to claim(s) 72 and 73, refer to the rejection of claim(s) 48 and 49 above.

With regard to claim(s) 74, refer to the rejection of claim(s) 50 above.

With regard to claim(s) 76 and 77, refer to the rejection of claim(s) 52 and 53 above.

With regard to claim(s) 81 and 82, Ledford teaches two distinct probes (fig. 1, Invader Oligonucleotide, WT Probe, invasive cleavage structure, for example).

With regard to the above claims, Ledford does not expressly teach the use of a probe that when hybridized to the target nucleic acid forms a duplex secondary structure, the formation of a DNA/RNA heteroduplex, or the detection of microRNA fewer than 30 nucleotides.

With regard to the use of probes having secondary structure, Lane provides a supportive disclosure that teaches oligonucleotide probes having a secondary structure wherein the duplex and target regions are within one nucleotide of each other (col. 1-3, summary; col.7, lines 5-25; col. 8, lines 15-30; fig. 1, sections A-D, box 30, for example). Lane expressly teaches that the duplex region of the probe stabilizes, entropically, the target-specific region of the capture moiety and thereby favours formation of a target:probe duplex (col. 7, lines 30-40, for example).

With regard to the formation of a DNA/RNA heteroduplex, it is noted that Ledford teaches the use of DNA to detect a DNA target; however, it is first noted that Prudent (U.S. 5,985,557), part of the original inventive entity of the Invader Assay, expressly envisioned the detection of RNA (col. 10, lines 25-40, for example). Furthermore, it was well known in the art at the time of invention that DNA probes could be used to detect RNA targets. For example, Rather outlines the well known "Northern Blot" assay which utilizes DNA probes to detect RNA targets (col. 12, lines 50-65, for example). Also, it was well known in the art at the time of invention that DNA was a more stable molecule than RNA (see Rando, U.S. 5,593,835; col. 10, lines 10-20, for example). Thus, it is submitted that one a skill in the art would have found it more practical to select DNA probes over RNA probes for the detection a target sequence due to the instability of RNA. Ledford did not teach the use of dual hairpin probes for detection, and did not teach detecting miRNA.

Dattagupta teaches the use of two hairpin probes for RNA detection, for example at column 9, line 22. Dattagupta did not disclose microRNA detection.

With regard to the detection of microRNA and claim(s) 51, 54, 75, and 78, Lau provides a supporting disclosure that teaches two types of short RNAs, both about 21 to 25 nucleotides

(21-25 nt) in length (lin-4 and let-7) (i.e. microRNA (miRNA)) (abstract; table 1, for example), an obvious structurally equivalent species of the genus molecule RNA. Lau further teaches the detection of miRNAs (fig. 3, for example) as well as the motivation to study these molecules, as their abundance implies that they function in a variety of regulatory pathways.

It would have been *prima facie* obvious to one of ordinary skill in that at the time of invention to incorporate two probes comprising secondary structure (i.e. hairpin structures) into the general, well known, Invader Assay as demonstrated by Ledford since the prior art suggests such a modification to stabilize and enhance formation of target duplex formation. An artisan would have been capable of applying this known method of enhancement, i.e. favoring a target:probe formation, to a probe based assay in a predictable manner.

Furthermore, it would have been *prima facie* obvious to one of ordinary skill in that at the time of invention to utilize DNA probes constructed to be used in the invader assay to detect RNA target since not only did the prior art recognize that DNA probes could be used in such a manner, DNA probes are more stable than their RNA counterparts. An artisan would have been capable of applying DNA probes (within the Invader Assay) to detect RNA targets in a predictable manner.

Furthermore, it would have been *prima facie* obvious to one of ordinary skill in that at the time of invention to apply the RNA detection methods of Ledford and Prudent, i.e. the Invader Assay, to microRNA, an obvious structurally equivalent species of the genus molecule RNA, since prior art suggests the detection and further study of these molecules because their abundance implies that they function in a variety of regulatory pathways.

In conclusion, given the small structure of microRNA, one of ordinary skill in the art would have been motivated to search for and apply techniques that would favor formation of target:probe formation, e.g. addition of secondary structure to probes, the use of DNA probes to detect RNA target, etc.

Claim(s) 33, 36, 44-47, 58, 59, 62, and 68-71 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. (J Mol Diagn. 2000 May;2(2):97-104) in view of Lane et al. (U.S. 5,770,365), in view of Prudent et al. (U.S. 5,985,557), Dattagupta et al. (U. S. Patent Number 5,215,899), Rather (U.S. 5,858,367), (U.S. 5,593,835), and Lau et al. (Science. 26 October 2001. Vol. 294: Pages 858-862), as applied to claim(s) 32 and 57, and in further view of Morris et al. J Clin Microbiol. 1996 Dec;34(12):2933-6).

The teachings of the previously applied references have been outlined in above rejections. The above references do not expressly teach a detection procedure that includes the polymerase chain reaction (PCR), more specifically, a PCR that utilizes a fluorescent probe configured for FRET detection.

Morris provides a supporting disclosure that teaches TaqMan RT-PCR encompassing the limitations set forth in the above claims (fig. 1; pg. 2934, Materials and Methods, RT-PCR, for example). Furthermore, they teach that in the TaqMan assay post amplification manipulations are reduced therefore offering significant time savings.

Thus, it would have been *prima facie* obvious to a skilled artisan at the time of invention to incorporate TaqMan PCR detection into the general, well known, Invader Assay as

demonstrated by Ledford since prior art suggests such a modification to allow homogeneous detection thereby reducing experimental time. A skilled artisan would have been capable of applying this known method of enhancement, i.e. reducing experimental time, to a probe based assay in a predictable manner.

Claim(s) 42, 43, 66, and 67 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. (J Mol Diagn. 2000 May;2(2):97-104) in view of Lane et al. (U.S. 5,770,365), in view of Prudent et al. (U.S. 5,985,557), Dattagupta et al. (U. S. Patent Number 5,215,899), Rather (U.S. 5,858,367), (U.S. 5,593,835), and Lau et al. (Science. 26 October 2001. Vol. 294: Pages 858-862), as applied to claim(s) 32 and 57, and in further view of Marras et al.)Genet Anal. 1999 Feb;14(5-6):151-6).

The teachings of the previously applied references have been outlined in above rejections. The above references do not expressly teach detection procedures that include the use of probes that form different conformations upon hybridization or the detection of polymorphisms.

Marras provides a supporting disclosure that teaches detection of single-nucleotide variants (pg. 154, col. 2, for example) through the incorporation of FRET enabled molecular beacons in a homogeneous assay (fig. 1; pg. 152, col. 2, for example). Furthermore, Marras teaches that molecular beacons are uniquely suited for the detection of single-nucleotide variants because they bind their targets with higher specificity than conventional oligonucleotide probes (pg. 152, col. 1, for example).

Thus, it would have been *prima facie* obvious to a skilled artisan at the time of invention to incorporate FRET enabled molecular beacons into the general, well known, Invader Assay as demonstrated by Ledford since prior art suggests such a modification to allow homogeneous detection. Moreover, the probes bind their targets with higher specificity than conventional oligonucleotide probes. A skilled artisan would have been capable of applying this known method of enhancement, i.e. homogeneous detection, to a probe based assay in a predictable manner.

Claim(s) 55, 56, 79, and 80 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ledford et al. (J Mol Diagn. 2000 May;2(2):97-104) in view of Lane et al. (U.S. 5,770,365), in view of Prudent et al. (U.S. 5,985,557), Dattagupta et al. (U. S. Patent Number 5,215,899), Rather (U.S. 5,858,367), (U.S. 5,593,835), and Lau et al. (Science. 26 October 2001. Vol. 294: Pages 858-862), as applied to claim(s) 32 and 57, and in further view of Hyldig-Nielsen et al. (U.S. 5,985,563).

The teachings of the previously applied references have been outlined in above rejections. The above references do not expressly teach the use of peptide nucleic acids (PNAs).

Hyldig-Nielsen provides a supporting disclosure that teaches an assay using PNA probes (col. 17, lines 30-45; col. 19,20, ex. 1, for example). Hyldig-Nielsen further teaches that PNAs have a higher thermal instability of mismatching bases whereby PNAs exhibit a greater specificity for their complementary nucleic acids than traditionally used nucleic acid probes (col. 2, lines 40-55).

Thus, it would have been *prima facie* obvious to a skilled artisan at the time of invention to incorporate PNA probes into the general, well known, Invader Assay as demonstrated by Ledford since prior art suggests such a modification to provide for probes with greater specificity. A skilled artisan would have been capable of applying this known method of enhancement, i.e. probes with greater specificity, to a probe based assay in a predictable manner.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 32-34, 36, 39-71, 73-80 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 21-23 and 29-33 of copending Application No. 11/929,878. Although the conflicting claims are not identical, they are not patentably distinct from each other because the competing application contains claims to the kit that contains all reagents required to perform the instant method, and for same purpose.

The instant methods drawn to the use of methods that employ sequence analysis, PCR, microarray hybridization, ligation, FRET, detection of polymorphisms, the use of PNA's and probes comprising nucleotide analogs, and signal amplification (i.e. 35-38, 44-47, 58-61, 63-65, 67, 69, 70, 77, and 80) are contemplated in the specification of the competing application and are therefore within the scope of the present invention and form a definition of what the invention covers, and their inclusion in this rejection is therefore considered proper.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 32-34, 36, 39-71, 73-80 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12, and 15-18 of copending Application No. 11/809,567. Although the conflicting claims are not identical, they are not patentably distinct from each other because the competing application contains claims to the kit that contains all reagents required to perform the instant method, and for same purpose. The instant methods drawn to the use of methods that employ PCR to achieve signal amplification, the use of PNA's and probes comprising nucleotide analogs, or to detect polymorphisms (i.e. 44, 47, 55, 56, 58-61, 77, 79 and 80) are contemplated in the specification of the competing application and are therefore within the scope of the present invention and form a definition of what the invention covers, and their inclusion in this rejection is therefore considered proper.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. Douglas Schultz, Ph.D. whose telephone number is 571-272-0763. The examiner can normally be reached on 8:00-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached at 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

JDS